Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16709897 | 1.00 | KMT2A (0.47) | KMT2AMEN1LMNASMN1; SMN2MAPT | |
| SCHEMBL17142153 | 1.00 | KMT2A (0.47) | KMT2AMEN1LMNASMN1; SMN2MAPT | |
| SCHEMBL17152752 | 0.85 | MEN1 (0.45) | KMT2AMEN1LMNASMN1; SMN2MAPT | |
| SCHEMBL18094318 | 0.84 | CYP4F2 (0.56) | KMT2ALMNASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL18094319 | 0.84 | CYP4F2 (0.56) | KMT2ALMNASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL3595923 | 0.83 | KMT2A (0.55) | KMT2AMEN1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL25706410 | 0.83 | KMT2A (0.55) | KMT2AMEN1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL11341741 | 0.83 | PTGS2 (0.63) | KMT2AMEN1LMNAMAPTALDH1A1 | |
| SCHEMBL3595919 | 0.83 | KMT2A (0.55) | KMT2AMEN1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL31079415 | 0.83 | KMT2A (0.55) | KMT2AMEN1SMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3325465-B1 | PESTICIDALLY ACTIVE PYRAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2022-05-18 | — | — | EP | disclosed |
| EP-3325465-A2 | PESTICIDALLY ACTIVE PYRAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2018-05-30 | — | — | EP | disclosed |
| US-20170137413-A1 | NOVEL HALOGEN-SUBSTITUTED COMPOUNDS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-05-18 | — | — | US | disclosed |
| EP-3126353-A1 | NOVEL 3-[(PYRAZOL-5-YL)-HETEROARYL]-BENZAMIDE DERIVATIVES AND USE THEREOF AS PEST CONTROL AGENTS | Bayer CropScience Aktiengesellschaft (DE) | 2017-02-08 | — | — | EP | disclosed |
| WO-2017012970-A2 | PESTICIDALLY ACTIVE PYRAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-01-26 | — | — | WO | disclosed |
| WO-2015150442-A1 | NOVEL 3-[(PYRAZOL-5-YL)-HETEROARYL]-BENZAMIDE DERIVATIVES AND USE THEREOF AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AG (DE) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137413-A1 | NOVEL HALOGEN-SUBSTITUTED COMPOUNDS | CYP4F3, PYM1, PRDX4 | KMT2A 1601/4885MEN1 1013/4885LMNA 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.